Decades of Brown Fat Research Studied the Wrong Cell

Brown fat has been studied as an energy-burning cell for decades. A new paper argues the field has been looking at the wrong thing entirely.

The thermogenic capacity of brown fat does not come from the adipocyte itself. It comes from the infrastructure around it — specifically, the nerve fibers that tell it to burn and the blood vessels that feed it fuel and carry away the heat. A team at NYU College of Dentistry, publishing in Nature Communications, has identified the molecular mechanism that builds both simultaneously: one protein, cleaved into two independent fragments, each controlling a different piece of that infrastructure. The researchers call it a split-signal architecture — an elegant evolutionary design in which two components of a single factor independently regulate distinct processes that must be tightly coordinated in space and time.

The protein is called SLIT3. The cleaving enzyme is BMP1, a protease that cuts SLIT3 into two fragments. The N-terminal fragment, SLIT3-N, drives blood vessel growth in brown fat. The C-terminal fragment, SLIT3-C, expands the nerve network through a receptor called PLXNA1. Remove either fragment — or its target — and brown fat loses one of its two support systems. The mice become cold-sensitive and cannot maintain body temperature. Their brown fat tissue, examined under a microscope, shows depleted nerve density and sparse blood vessel networks.

According to ScienceDaily's report on the findings, researchers examined brown fat tissue from mice missing SLIT3 or its receptor, finding deficient nerve structure and vascular density. Human genetics point in the same direction: examining fat tissue from more than 1,500 people with and without obesity, the team found that SLIT3 gene expression is linked to fat tissue health, inflammation, and insulin sensitivity — a finding consistent across the GWAS data.

This reframes what brown fat actually is. The field has spent years studying the adipocyte as the central actor in thermogenesis. The Shamsi lab's work suggests the real story is the wiring. "Brown fat acts like a metabolic sink that draws in nutrients and prevents them from being stored," the researchers explained in their release — but that sink only works if the inflow and signaling infrastructure is in place.

The therapeutic angle is where this gets commercially interesting. GLP-1 drugs — Novo Nordisk's Wegovy and Eli Lilly's Zepbound — work by making people eat less. They have proven extraordinarily effective. They are also, by design, a ceiling: you cannot outdiet a body that wants to store energy. The SLIT3 pathway proposes something structurally different. Rather than reducing caloric intake, it proposes increasing energy expenditure — making the body burn more by improving the hardware that enables burning. One protein, two independent developmental programs, multiple potential drug targets.

The mechanism has drawbridges. BMP1 is the protease, so inhibiting it would suppress both signals simultaneously — probably not useful. But selectively activating SLIT3-N or SLIT3-C independently could theoretically boost either the vascular or neural arm of brown fat thermogenesis without touching the other. The PLXNA1 receptor for SLIT3-C is identified, which opens the door to fragment-specific agonism. The split-signal design means you could, in principle, tune one axis without the other.

Co-author Tamires Duarte Afonso Serdan received a $275,812 postdoctoral fellowship from the American Diabetes Association in 2026 to study SLIT3 signaling in adipose tissue — a sign the lab is treating this as a multi-year research program, not a one-paper finding. The work was funded by the NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the G. Harold and Leila Y. Mathers Foundation, the German Research Foundation, the German Center for Diabetes Research, and the American Heart Association. The full list of funders is in the preprint on bioRxiv.

One co-author's financial disclosures deserve prominent mention. Matthias Blüher, a senior researcher based at Leipzig University in Germany, has consulting relationships with Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, Bayer, Boehringer-Ingelheim, Amgen, and Novartis — the companies most invested in the GLP-1 market and in obesity therapeutics broadly. That does not make the science wrong. It does mean the commercial implications of this pathway are being evaluated by parties with substantial financial interests in the answer.

Brown fat thermogenesis via SLIT3 is not a new idea waiting for a paper. It is a newly mapped architecture. The distance from describing a split-signal mechanism to designing a drug that safely exploits it remains very long — past efforts to directly stimulate brown fat thermogenesis have run into cardiovascular safety problems that killed several programs. But the split-signal design, if it holds in humans, offers more handles to work with than a single target did. Whether those handles lead anywhere will require years of pharmacology and, eventually, clinical data that does not yet exist.

The paper is available in Nature Communications.